What clinical features indicate that gangrene is caused by vasculitis?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 17, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Clinical Features Indicating Vasculitis-Induced Gangrene

When gangrene occurs in the context of vasculitis, look for multi-system involvement, positive ANCA serology (MPO or PR3), elevated inflammatory markers, and characteristic patterns of tissue necrosis affecting small vessels—particularly when accompanied by palpable purpura, peripheral neuropathy, or glomerulonephritis. 1

Key Distinguishing Features of Vasculitic Gangrene

Systemic Manifestations

Vasculitis-related gangrene rarely occurs in isolation. According to the 2024 KDIGO guidelines, small-vessel vasculitis characteristically involves multiple organ systems 1:

  • Upper and lower respiratory tract involvement (sinusitis, pulmonary nodules, alveolar hemorrhage)
  • Renal manifestations: Rapidly progressive glomerulonephritis with microscopic hematuria, dysmorphic red blood cells, red cell casts, and moderate proteinuria (1-3 g/day) 1
  • Neurologic involvement: Mononeuritis multiplex presenting as asymmetric sensorimotor deficits 2, 3
  • Ocular manifestations: Episcleritis, scleritis, or retro-orbital disease 1

Cutaneous Patterns

The skin manifestations provide critical diagnostic clues 4, 5:

  • Palpable purpura (most common presentation of small-vessel vasculitis)
  • Digital gangrene affecting fingertips and toes, often bilateral
  • Livedo racemosa (irregular, broken network pattern)
  • Deep ulcers with necrotic bases
  • Pan-dermal involvement extending from superficial to deep vessels

Critical distinction: Vasculitic gangrene typically shows palpable peripheral pulses with normal ankle-brachial index, unlike atherosclerotic peripheral arterial disease 2. This indicates small-vessel rather than large-vessel occlusion.

Laboratory Markers

Approximately 90% of patients with small-vessel vasculitis have positive ANCA 1:

  • MPO-ANCA (more common in microscopic polyangiitis)
  • PR3-ANCA (more common in granulomatosis with polyangiitis)
  • Markedly elevated inflammatory markers: ESR and CRP are typically significantly elevated 2, 6, 3
  • ANCA negativity does not exclude vasculitis in the appropriate clinical context 1

The 2024 KDIGO guidelines emphasize that high-quality antigen-specific immunoassays for MPO and PR3 are the preferred screening method 1.

Histopathologic Confirmation

Biopsy remains the gold standard 7:

  • Necrotizing inflammation of small vessels (arterioles, capillaries, venules)
  • Pauci-immune pattern: Little to no immune complex deposition in vessel walls 1
  • Leukocytoclastic changes with neutrophilic infiltration
  • Fibrinoid necrosis of vessel walls

For digital gangrene, sural nerve biopsy can be diagnostic, showing vasculitis with axonal damage and perivascular inflammation 8, 2.

Specific Vasculitis Contexts

ANCA-Associated Vasculitis (AAV)

The most common cause of vasculitic gangrene includes GPA, MPA, and EGPA 1. Pulmonary-renal syndrome (simultaneous lung hemorrhage and rapidly declining GFR) is particularly suggestive and carries increased mortality risk 1.

Rheumatoid Vasculitis

Typically occurs in longstanding, severe, seropositive RA with high RF (>200 U/mL) and ACPA (>300 U/mL) 9, 2, 3. However, early presentation is possible in inadequately treated disease 2, 3. Look for:

  • Active polyarthritis (multiple joint involvement)
  • Peripheral neuropathy preceding gangrene
  • Elevated inflammatory markers despite joint symptoms

Lupus-Associated Vasculitis

Extremely rare as initial presentation (only 0.2% of SLE cases) 10. When present:

  • Often accompanied by lupus nephritis
  • Petechial rash on lower extremities
  • Positive ANA, anti-dsDNA, low complement levels
  • May have elevated anti-endothelial cell antibodies 8

Common Pitfalls to Avoid

  1. Don't assume atherosclerotic disease: Presence of palpable pulses with digital gangrene suggests vasculitis, not large-vessel occlusion 2

  2. Don't wait for biopsy to treat: The 2024 KDIGO guidelines explicitly state that in rapidly deteriorating patients with compatible clinical presentation and positive MPO/PR3-ANCA, immunosuppressive therapy should not be delayed 1, 11

  3. Don't overlook ANCA-negative vasculitis: 10% of small-vessel vasculitis cases are ANCA-negative 1

  4. Consider alternative causes: Rule out thrombotic disorders (antiphospholipid syndrome), cryoglobulinemia, and drug-induced vasculitis 4, 6

  5. Assess for macrovascular disease: In systemic sclerosis patients, 18.6% with digital gangrene had macrovascular stenosis 6

Diagnostic Algorithm

When evaluating gangrene for vasculitic etiology:

  1. Check peripheral pulses and ABI → Normal suggests small-vessel disease
  2. Screen for systemic involvement → Urinalysis (hematuria, proteinuria, casts), chest imaging, neurologic examination
  3. Obtain ANCA testing → MPO and PR3 by antigen-specific immunoassay 1, 7
  4. Measure inflammatory markers → ESR, CRP (typically markedly elevated) 2, 6
  5. Consider additional autoantibodies → ANA, RF, ACPA, antiphospholipid antibodies based on clinical context 2, 6
  6. Pursue tissue diagnosis → Skin biopsy extending to subcutis from most tender/purpuric area, or nerve biopsy if neuropathy present 4, 2

The combination of multi-organ involvement, positive ANCA serology, markedly elevated inflammatory markers, and characteristic histopathology establishes vasculitis as the cause of gangrene 1, 7.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.